Evidence map›Paper›PMID 42835324›Full record

ArticleVeterinary and animal science2026

Prospective, randomized, placebo-controlled, multicenter, double-blind, parallel-group, registration field trial evaluating izenivetmab, a caninized anti-nerve growth factor monoclonal antibody, administered quarterly to dogs with naturally occurring osteoarthritis.

Hilde Moyaert, Gina M Michels, Helena Berlamont, Karen Akkermans, Bernard D Hummel, Jezaniah Kira S Tena, Maria J Corral, Ignacio Gisbert, Dawn M Cleaver, Michael R Stegemann

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Veterinary and animal science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Hilde MoyaertVeterinary Medicine Research and Development, Zoetis Belgium SA, Zaventem, Belgium.
Gina M MichelsVeterinary Medicine Research and Development, Zoetis Inc., Kalamazoo, MI, USA.
Helena BerlamontVeterinary Medicine Research and Development, Zoetis Belgium SA, Zaventem, Belgium.
Karen AkkermansVeterinary Medicine Research and Development, Zoetis Belgium SA, Zaventem, Belgium.
Bernard D HummelVeterinary Medicine Research and Development, Zoetis Inc., Kalamazoo, MI, USA.
Jezaniah Kira S TenaVeterinary Medicine Research and Development, Zoetis Inc., Kalamazoo, MI, USA.
Maria J CorralVeterinary Medicine Research and Development, Zoetis Belgium SA, Zaventem, Belgium.
Ignacio GisbertVeterinary Medicine Research and Development, Zoetis Belgium SA, Zaventem, Belgium.
Dawn M CleaverVeterinary Medicine Research and Development, Zoetis Inc., Kalamazoo, MI, USA.
Michael R StegemannVeterinary Medicine Research and Development, Zoetis Belgium SA, Zaventem, Belgium.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Izenivetmab, a caninized monoclonal antibody that targets nerve growth factor, was evaluated for osteoarthritis-related pain in a prospective, randomized, placebo-controlled, double-blind, parallel-group field trial, conducted at multiple private practices, enrolling 574 individually owned dogs (median age, 9.0 years) with osteoarthritis (e.g., moderate to nearly incapacitating). Dogs were block randomized (1:1) to izenivetmab (

Indexed as

Canine brief pain inventoryCanine osteoarthritisIzenivetmabMonoclonal antibodyPain management

Identifiers

PMID42835324
PMCPMC13635250

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.